This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.

Smolen, J., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Purcaru, O., Bennett, B., Burkhardt, H., Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial, <<ANNALS OF THE RHEUMATIC DISEASES>>, 2015; 74 (5): 843-850. [doi:10.1136/annrheumdis-2013-204632] [http://hdl.handle.net/10807/71518]

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Ferraccioli, Gianfranco;
2015

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Inglese
Smolen, J., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Purcaru, O., Bennett, B., Burkhardt, H., Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial, <<ANNALS OF THE RHEUMATIC DISEASES>>, 2015; 74 (5): 843-850. [doi:10.1136/annrheumdis-2013-204632] [http://hdl.handle.net/10807/71518]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/71518
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 80
  • ???jsp.display-item.citation.isi??? 74
social impact